CN110382530A - 亚型特异性、背景许可性TGFβ1抑制剂及其用途 - Google Patents

亚型特异性、背景许可性TGFβ1抑制剂及其用途 Download PDF

Info

Publication number
CN110382530A
CN110382530A CN201880015969.2A CN201880015969A CN110382530A CN 110382530 A CN110382530 A CN 110382530A CN 201880015969 A CN201880015969 A CN 201880015969A CN 110382530 A CN110382530 A CN 110382530A
Authority
CN
China
Prior art keywords
tgfβ1
antibody
tgf
seq
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880015969.2A
Other languages
English (en)
Chinese (zh)
Inventor
T·舒尔普夫
A·达塔
G·J·卡文
C·马丁
A·卡尔拉
K·朗
A·巴克勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stone Supply Co
Original Assignee
Stone Supply Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stone Supply Co filed Critical Stone Supply Co
Priority to CN202310792211.2A priority Critical patent/CN117398457A/zh
Publication of CN110382530A publication Critical patent/CN110382530A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CN201880015969.2A 2017-01-06 2018-01-05 亚型特异性、背景许可性TGFβ1抑制剂及其用途 Pending CN110382530A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310792211.2A CN117398457A (zh) 2017-01-06 2018-01-05 亚型特异性、背景许可性TGFβ1抑制剂及其用途

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201762443615P 2017-01-06 2017-01-06
US62/443,615 2017-01-06
US201762452866P 2017-01-31 2017-01-31
US62/452,866 2017-01-31
US201762514417P 2017-06-02 2017-06-02
US62/514,417 2017-06-02
US201762529616P 2017-07-07 2017-07-07
US62/529,616 2017-07-07
US201762549767P 2017-08-24 2017-08-24
US62/549,767 2017-08-24
US201762558311P 2017-09-13 2017-09-13
US62/558,311 2017-09-13
US201762585227P 2017-11-13 2017-11-13
US62/585,227 2017-11-13
US201762587964P 2017-11-17 2017-11-17
US62/587,964 2017-11-17
US201762588626P 2017-11-20 2017-11-20
US62/588,626 2017-11-20
PCT/US2018/012601 WO2018129329A1 (en) 2017-01-06 2018-01-05 ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310792211.2A Division CN117398457A (zh) 2017-01-06 2018-01-05 亚型特异性、背景许可性TGFβ1抑制剂及其用途

Publications (1)

Publication Number Publication Date
CN110382530A true CN110382530A (zh) 2019-10-25

Family

ID=61198888

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880015969.2A Pending CN110382530A (zh) 2017-01-06 2018-01-05 亚型特异性、背景许可性TGFβ1抑制剂及其用途
CN202310792211.2A Pending CN117398457A (zh) 2017-01-06 2018-01-05 亚型特异性、背景许可性TGFβ1抑制剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310792211.2A Pending CN117398457A (zh) 2017-01-06 2018-01-05 亚型特异性、背景许可性TGFβ1抑制剂及其用途

Country Status (17)

Country Link
US (3) US20180207267A1 (cg-RX-API-DMAC7.html)
EP (1) EP3551658A1 (cg-RX-API-DMAC7.html)
JP (3) JP7157744B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240137126A (cg-RX-API-DMAC7.html)
CN (2) CN110382530A (cg-RX-API-DMAC7.html)
AU (2) AU2018205231A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019013908A2 (cg-RX-API-DMAC7.html)
CA (1) CA3049005A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001874A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019007298A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190350A (cg-RX-API-DMAC7.html)
DO (1) DOP2019000180A (cg-RX-API-DMAC7.html)
IL (2) IL267790A (cg-RX-API-DMAC7.html)
MX (1) MX429001B (cg-RX-API-DMAC7.html)
PE (1) PE20191661A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501575A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018129329A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体
CN115190812A (zh) * 2020-01-11 2022-10-14 供石公司 TGFβ抑制剂及其用途

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
CN110382530A (zh) * 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
EP3658583A1 (en) * 2017-07-28 2020-06-03 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
KR102891320B1 (ko) 2018-07-11 2025-11-28 스칼러 락, 인크. 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
PT3677278T (pt) 2018-07-11 2022-02-03 Scholar Rock Inc Inibidores seletivos da isoforma tgfbeta1 e sua utilização
EP3820896A1 (en) 2018-07-11 2021-05-19 Scholar Rock, Inc. TGFbeta1 INHIBITORS AND USE THEREOF
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
SG11202108099WA (en) 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
SG11202110338XA (en) 2019-03-27 2021-10-28 Singapore Health Serv Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis
WO2020206055A1 (en) * 2019-04-02 2020-10-08 Yale University Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CN120022360A (zh) 2019-08-28 2025-05-23 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20230122364A1 (en) * 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
BR112022021780A2 (pt) 2020-04-27 2023-03-07 Twist Bioscience Corp Bibliotecas de ácido nucléico variantes para coronavírus
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN116723861A (zh) * 2020-12-02 2023-09-08 上海复宏汉霖生物技术股份有限公司 抗GARP/TGFβ抗体及使用方法
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
US20250282857A1 (en) * 2021-03-26 2025-09-11 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
JP7892764B2 (ja) * 2021-08-11 2026-07-21 イミュニティーバイオ インコーポレイテッド 多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN119255993A (zh) 2022-03-22 2025-01-03 奥托泰利克生物公司 噻唑衍生物化合物及其用途
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4676954A1 (en) 2023-03-07 2026-01-14 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN117721079B (zh) * 2024-01-26 2025-03-11 广东壹加再生医学研究院有限公司 一种促进nk细胞抗肿瘤活性的培养基及培养方法
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745102A (zh) * 2002-12-27 2006-03-08 多曼蒂斯有限公司 特异性针对配体及其受体的双特异性单区抗体
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
US20120201781A1 (en) * 2011-02-08 2012-08-09 Abbott Laboratories Treatment of osteoarthritis and pain
CN102807617A (zh) * 2003-09-10 2012-12-05 沃尼尔·朗伯有限责任公司 M-csf的抗体
US20120315282A1 (en) * 2011-06-03 2012-12-13 Xoma Technology Ltd. Antibodies Specific for TGF-Beta
CN103214577A (zh) * 2007-03-22 2013-07-24 拜奥根Idec马萨诸塞公司 特异性结合cd154 的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
WO2014182676A2 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CN104271599A (zh) * 2011-11-08 2015-01-07 辉瑞公司 使用抗m-csf抗体治疗炎性疾病的方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
JPH11507843A (ja) 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
SMT201800092T1 (it) 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
WO2015171691A2 (en) * 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
SG11201705721WA (en) * 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
CN110382530A (zh) * 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745102A (zh) * 2002-12-27 2006-03-08 多曼蒂斯有限公司 特异性针对配体及其受体的双特异性单区抗体
CN102807617A (zh) * 2003-09-10 2012-12-05 沃尼尔·朗伯有限责任公司 M-csf的抗体
CN103214577A (zh) * 2007-03-22 2013-07-24 拜奥根Idec马萨诸塞公司 特异性结合cd154 的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
US20120201781A1 (en) * 2011-02-08 2012-08-09 Abbott Laboratories Treatment of osteoarthritis and pain
US20120315282A1 (en) * 2011-06-03 2012-12-13 Xoma Technology Ltd. Antibodies Specific for TGF-Beta
CN104271599A (zh) * 2011-11-08 2015-01-07 辉瑞公司 使用抗m-csf抗体治疗炎性疾病的方法
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
WO2014182676A2 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANIEL BEDINGER: "Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms", 《MABS》 *
GENBANK: ""Accession No.:ABD59021.1,anti-TREM-like transcript-1 antibody[synthetic construct]"", 《GENBANK》 *
YOSHIKI YANAGAWA: "Isoform-specific regulation of transforming growth factor-β mRNA expression in macrophages in response to adrenoceptor stimulation", 《MICROBIOLOGY IMMUNOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115190812A (zh) * 2020-01-11 2022-10-14 供石公司 TGFβ抑制剂及其用途
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体

Also Published As

Publication number Publication date
JP2022188226A (ja) 2022-12-20
IL304416A (en) 2023-09-01
CR20190350A (es) 2019-11-15
JP7157744B2 (ja) 2022-10-20
WO2018129329A1 (en) 2018-07-12
US20240016928A1 (en) 2024-01-18
AU2018205231A1 (en) 2019-07-18
KR20190098255A (ko) 2019-08-21
CO2019007298A2 (es) 2019-07-31
US20180207267A1 (en) 2018-07-26
JP2020503362A (ja) 2020-01-30
CN117398457A (zh) 2024-01-16
MX429001B (es) 2025-11-13
CL2019001874A1 (es) 2019-12-06
US20190209682A1 (en) 2019-07-11
BR112019013908A2 (pt) 2020-02-04
MX2019008197A (es) 2019-09-11
KR20240137126A (ko) 2024-09-19
AU2025203555A9 (en) 2026-03-12
CA3049005A1 (en) 2018-07-12
PH12019501575A1 (en) 2019-11-04
EP3551658A1 (en) 2019-10-16
AU2025203555A1 (en) 2025-06-05
DOP2019000180A (es) 2019-09-15
JP2025000891A (ja) 2025-01-07
PE20191661A1 (es) 2019-11-11
IL267790A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
US20240016928A1 (en) Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
JP7794630B2 (ja) TGFβ1結合性免疫グロブリンおよびその使用
KR102891320B1 (ko) 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
US12122823B2 (en) Isoform-selective TGFB1 inhibitors and use thereof
WO2020014473A1 (en) TGFβ1 INHIBITORS AND USE THEREOF
WO2021142427A1 (en) TGFβ INHIBITORS AND USE THEREOF
CA3105988C (en) High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof
EA045239B1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
EA051619B1 (ru) ИНГИБИТОРЫ TGFβ И ИХ ПРИМЕНЕНИЕ
EA049507B1 (ru) ВЫСОКОАФФИННЫЕ, СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ ИЗОФОРМЫ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
EA048751B1 (ru) TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191025

WD01 Invention patent application deemed withdrawn after publication